<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834286</url>
  </required_header>
  <id_info>
    <org_study_id>HE14-021</org_study_id>
    <nct_id>NCT02834286</nct_id>
  </id_info>
  <brief_title>Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia</brief_title>
  <official_title>Low-dose Rituximab in Combination With Eltrombopag and High-dose Dexamethasone as Frontline Treatment for Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the response rate and response duration with the
      combination of low-dose rituximab, eltrombopag and high-dose dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immune thrombocytopenia is an autoimmune disorder characterized by formation of
      autoantibodies against platelet antigens leading platelet destruction.

      Corticosteroids increase the platelet count in about 80 percent of patients. However, many
      patients have a relapse when the dose of corticosteroid is reduced. Debilitating side effects
      are common in patients who require long-term corticosteroid therapy to maintain the platelet
      count. Eltrombopag, it is a small molecule agonist of the c-mpl (TpoR) receptor, which is the
      physiological target of the hormone thrombopoietin, has been shown to be effectively raise
      the platelet count in adult patients (aged 18 years and over) who have had their spleen
      removed or where splenectomy is not an option and have received prior treatment with
      corticosteroids or immunoglobulins, and these medicines did not work (refractory ITP). There
      are a few case reports where eltrombopag was an option as first line treatment for IT.

      The purpose of this study is to determine the response rate and response duration with the
      combination of rituximab (100 mg weekly four weeks), eltrombopag (50mg PO once a day, day
      1-28) and high-dose dexamethasone (40mg PO days 1-4) in untreated adult patients with
      &lt;30*109/L platelet count diagnosed with immune thrombocytopenia.

      A complete response is defined as an increase in platelet counts to &gt;150×109/L on two
      consecutive occasions. A clinical response is defined as an increase in the platelet count
      between &gt;30×109/L on two consecutive measures and no bleeding. Duration of response is
      considered from the day of the initial administration to the first time of relapse (platelet
      count &lt;30×109/L) or to time of analysis Patients will be evaluated each week during 4 weeks
      and then every month for at least 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>28 days</time_frame>
    <description>Platelet counts to &gt;30×109/L on two consecutive occasions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>28 days</time_frame>
    <description>Platelet counts to &gt;100×109/L on two consecutive occasions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Rituximab, eltrombopag and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21 Eltrombopag 50 mg PO days 1-28 Dexamethasone 40 mg IV/PO days 1-4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 100 mg weekly days 1, 7, 14, 21</description>
    <arm_group_label>Rituximab, eltrombopag and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Eltrombopag 50 mg PO days 1-28</description>
    <arm_group_label>Rituximab, eltrombopag and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 40 mg IV/PO days 1-4</description>
    <arm_group_label>Rituximab, eltrombopag and dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically confirmed immune thrombocytopenic (IT) Platelet count less than 30,000/mm3
             on two ocasionts with bleeding.

          -  Subject ≥ 16 years

          -  Subject has signed and dated written informed consent.

          -  No sepsis or fever or active infection

          -  Not pregnant or nursing

        Exclusion Criteria:

          -  Previous treatment (only corticosteroids at dose or prednisone equivalent of 300 mg)

          -  Performance status above or equal to 2.

          -  Pregnancy and lactation

          -  Previous splenectomy

          -  Connective tissue disease

          -  Autoimmune hemolytic anemia

          -  Relapse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Gómez, MD</last_name>
    <phone>+5583486136</phone>
    <email>dgomezalmaguer@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Servicio de Hematología, Hospital Universitario &quot;Dr. José Eleuterio González&quot;, Universidad Autónoma de Nuevo León</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perla R Colunga, MD</last_name>
      <phone>+558110761973</phone>
      <email>colunga.perla@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Gómez-Almaguer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perla R. Colunga-Pedraza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Cantú-Rodríguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>César H. Gutiérrez-Aguirre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mónica Sánchez-Cárdenas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José C Jaime-Pérez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luz Tarín-Arzaga</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>González-López TJ, Alvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Jarque I, Pérez-Rus G, Pérez-Crespo S, Bernat S, Hernández-Rivas JA, Andrade MM, Cortés M, Gómez-Nuñez M, Olivera P, Martínez-Robles V, Fernández-Rodríguez A, Fuertes-Palacio MA, Fernández-Miñano C, de Cabo E, Fisac R, Aguilar C, Bárez A, Peñarrubia MJ, García-Frade LJ, González-Porras JR. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016 Sep;97(3):297-302. doi: 10.1111/ejh.12725. Epub 2016 Jan 27.</citation>
    <PMID>26709028</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, Kim HJ. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res. 2015 Mar;50(1):19-25. doi: 10.5045/br.2015.50.1.19. Epub 2015 Mar 24.</citation>
    <PMID>25830126</PMID>
  </results_reference>
  <results_reference>
    <citation>Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC, Gómez-De León A, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Tarín-Arzaga L, Hernández-Reyes J, Ruiz-Arguelles GJ. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014 Jun 19;123(25):3906-8. doi: 10.1182/blood-2014-01-549360. Epub 2014 May 6.</citation>
    <PMID>24802773</PMID>
  </results_reference>
  <results_reference>
    <citation>Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Sánchez-Cárdenas M. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013 Jun;90(6):494-500. doi: 10.1111/ejh.12102. Epub 2013 Apr 2.</citation>
    <PMID>23470153</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>Hematology division chief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

